Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Remdesivir Supplies: 'Peculiar' Situation, Flip Flops And Bangladesh Touch

Executive Summary

There's an action-packed run up to remdesivir supply plans in India replete with politics, with one state initially veering towards sourcing the potential COVID-19 treatment from Bangladesh, while pricing debate rumbles on. Indian licensees are now believed to have inched close to regulatory approval.

You may also be interested in...



India Remdesivir Supply Gap May Normalize Soon, But No End To Greed

 India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.

India Remdesivir Black Market: Supply Gap May Normalize Soon, But No End To Greed

India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.

Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress

Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC142386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel